Global Bare Metal Stents Market was Estimated at $1 billion in 2010

Monday 17 October 2011, Amsterdam

The global Bare Metal Stents (BMS) market was estimated to be worth about $1billion in 2010. The BMS market has declined from $1.9 billion in 2003 at a Compound Annual Growth Rate (CAGR) of 8.5%. The popularity and affordability of Drug Eluting Stents (DES) is negatively affecting the BMS market.

Declining Average Selling Prices (ASP) and decreasing penetration of BMS in the treatment of Coronary Heart Disease (CHD) will lead to a decline in the BMS market to $0.9 billion by 2017. The BMS market is expected to decline at a CAGR of 1.8% until 2017. However, the volumes of BMS are expected to rise due to a decrease in the prices of BMS, thereby leading to an increase in their affordability.
 

Increase in the Incidence of Coronary Heart Disease to Lead to an Increase in the Usage of Bare Metal Stents

An increase in the incidence of CHD will lead to an increase in the use of coronary stents in its treatment. In the US, at the current growth rate, the prevalence of the disease will rise to 9.3% by 2030 from 8% in 2010. This will lead to an increase of about eight million patients suffering from CHD. According to the National Health and Nutrition Examination Survey (NHANES) 2005-2008 data, about 16.3 million adults (>=20) suffer from CHD in the US. About 800,000 people will suffer from a new coronary attack annually, while 500,000 will suffer a recurring one.

An estimated 2.7 million people were suffering from CHD in 2010. The rate was higher in men compared to women. The British Heart Foundation (BHF) estimates that about 88,000 deaths occurred due to CHD in 2008.

An increase in the incidence of CHD is expected to lead to higher demand for BMS. The increase in incidence of CHD is due to the rising number of people suffering from risk factors such as obesity, diabetes, smoking, alcohol consumption and unhealthy lifestyles, as well as the issue of aging populations, among other things. Obesity is one of the leading causes of cardiovascular diseases and is known to be the underlying cause of about 23% of ischemic heart disease cases. The World Health Organization (WHO) estimates that about 105 million people globally are overweight.

For people with the underlying condition of diabetes, the probability of developing CVD increases by two to four times. According to the WHO and the World Diabetes Foundation, about 285 million people globally were affected with diabetes in 2010. By 2030, about 8% of the global population, comprising about 438 million people, is expected to suffer from diabetes. About 26 million people are affected by diabetes in the US. In the UK, about 2.1 million people suffer from diabetes. India and China have the largest numbers of patients suffering from diabetes. According to the World Diabetes Foundation, India had an estimated 50.8 million and China 43.2 million people suffering from diabetes in 2010. The age-group containing the highest percentage of people suffering from diabetes is the 40-59 age-group. By 2030, the individuals in this age-group will shift to the ‘aged 60 and over’ age-group. It is expected that about 196 million people aged 60 and over will suffer from diabetes in 2030.

The latest study, published in 2010, estimates that about 92 million people in China suffer from diabetes. It is projected that about 500 million people in China will suffer from diabetes by 2030.


The US Bare Metal Stents Market was the Largest Market Valued at $417m in 2010

The BMS market in the US was estimated at $417m in 2010, declining at a CAGR of 11.6% during the period 2003-2010. The revenues were negatively affected by the introduction of DES in 2003 and their acceptance in the treatment of CHD. The BMS market revived during the period 2005-2008, from $210.9m in 2005 to $513.8m in 2008. The market increased due to cautionary warnings on the use of DES, leading to an increased use of BMS.

The US is followed by Japan in being the second largest BMS market, valued at $200m in 2010. Japan has a large proportion of its population over the age of 65 years. In 2010, it was estimated that about 23% of the Japanese population were over the age of 65. The probability of developing CHD increases with increasing age. The BMS market in Japan has declined from $337m in 2003 at a CAGR of 6.7%.


Abbott Laboratories Dominates the Global Bare Metal Stents Market

Abbott Laboratories leads the global BMS market, with a share of 58%. Medtronic Inc. is the next largest player after Abbott Laboratories, with a market share of 16%. The entry of new players, such as Biosensors International and MicroPort Scientific Corporation, is leading to increased competition in the bare metal stents market. This is leading to a decrease in the ASP of BMS.

A recent development in June 2011 was the announcement of Cordis Corporation quitting the coronary stents market by the end of 2011. The exit of Cordis Corporation from the coronary stents market is expected to benefit major players such as Abbott Laboratories and Boston Scientific. It is also expected to give an opportunity to new market players to enter the coronary stents market.


About this new market study:
This report provides market landscape, competitive landscape and market trends information on the bare metal stents market. The report provides comprehensive information on the key trends affecting the market, and key analytical content on the market dynamics. The report also reviews the competitive landscape and technology offerings.